Platelet lysate

BIOLOGICAL5 trials

Sponsors

University of Jordan, Hanan Jafar, Sophia Al-Adwan, Regenexx, LLC

Conditions

Critical Limb IschemiaDiabetic Foot UlcerLumbar RadiculopathyLumbosacral RadiculopathyPeripheral Arterial DiseasePersistent Corneal Epithelial Defect

Phase 1

Treatment of PAD by Platelet Lysate for Therapeutic Angiogenesis

CompletedNCT02941419

University of JordanCritical Limb Ischemia

Start: 2013-03-05End: 2017-02-09Updated: 2017-05-04

The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer

Hanan JafarDiabetic Foot Ulcer

Start: 2018-02-03End: 2020-09-30Target: 30Updated: 2019-08-28

Autologous Platelet Lysate in Corneal Epithelial Defects

CompletedNCT02979912

Hanan JafarPersistent Corneal Epithelial Defect

Start: 2017-02-16End: 2019-01-30Updated: 2021-03-03

Use of Allogenic Platelet Lysate in Peripheral Arterial Disease (PAD)

Sophia Al-AdwanPeripheral Arterial Disease

Start: 2018-04-18End: 2020-05-31Target: 20Updated: 2019-07-24

Unknown Phase

Platelet Lysate vs Saline for Lumbosacral Radiculopathy

TerminatedNCT06924853

Regenexx, LLCLumbar Radiculopathy, Lumbosacral Radiculopathy

Start: 2025-07-01End: 2025-11-05Updated: 2026-02-25

Related Papers

Platelet lysate promotes re-epithelialization of persistent epithelial defects: a pilot study.

2018-07-059 citations